Date: 2013-03-05
Type of information: Development agreement
Compound: alpha7 NNR modulators, alpha4beta2 NNR modulators including AZD1446 and TC-1734
Company: AstraZeneca (UK) Targacept (USA)
Therapeutic area: CNS diseases - Mental diseases - Psychiatric diseases - Neurodegenerative diseases
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease: cognitive disorders, schizophrenia, Alzheimer’s disease
Details: Targacept and AstraZeneca have amended their collaboration. Under the new terms, Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator in any therapeutic area, including cognitive disorders and schizophrenia, without obligation to AstraZeneca. Previously, AstraZeneca held an option to license any such compound that was developed by Targacept for a cognitive disorder or schizophrenia.
TC-5619, Targacept’s most advanced alpha7 NNR modulator, is currently in a Phase 2b clinical trial as a treatment for negative symptoms and cognitive dysfunction in schizophrenia. Top-line results from this study are expected by the end of 2013. Targacept is also evaluating potential Phase 2 development of TC-5619 as a treatment for Alzheimer’s disease. Beyond TC-5619, Targacept has several alpha7 NNR modulators in its chemical library. The most advanced of these compounds is the Phase 2-stage TC-6987, and Targacept is evaluating potential future development options for this product candidate.
AstraZeneca has the right to develop and commercialize the alpha4beta2 NNR modulators that it has licensed from Targacept under the collaboration, including AZD1446, in any therapeutic area. Previously, AstraZeneca’s rights with regard to these compounds were limited to cognitive disorders and schizophrenia. AstraZeneca will also return to Targacept all rights to the alpha4beta2 modulator TC-1734 (also known as AZD3480), which is currently in a Phase 2b clinical trial in mild to moderate Alzheimer’s disease.
Targacept and AstraZeneca entered into their global collaboration agreement focused on cognitive disorders in December 2005.
Financial terms:
Latest news:
